PriceTargets.com logo

Seaport Therapeutics - SPTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $38.57
  • Forecasted Upside: 114.64%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$17.97 As of 10/8/2026 04:40 PM ET
▲ +0.04 (0.22%)

This chart shows the closing price for SPTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Seaport Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPTX

Analyst Price Target is $38.57
▲ +114.64% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Seaport Therapeutics in the last 3 months. The average price target is $38.57, with a high forecast of $50.00 and a low forecast of $30.00. The average price target represents a 114.64% upside from the last price of $17.97.

This chart shows the closing price for SPTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 polled investment analysts is to moderate buy stock in Seaport Therapeutics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/16/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/15/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/13/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/11/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/11/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
7/10/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
9/8/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
10/8/2026

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/8/2026UBS GroupReiterated RatingBuy ➝ Buy
10/8/2026HC WainwrightReiterated RatingBuy ➝ Buy$50.00
9/25/2026Weiss RatingsDowngradeSell (D+) ➝ Sell (D)
9/25/2026Raymond James FinancialInitiated CoverageStrong-Buy$46.00
9/25/2026Raymond James FinancialInitiated CoverageStrong-Buy$46.00
9/10/2026HC WainwrightReiterated RatingBuy ➝ Buy$50.00
8/26/2026JonesTradingInitiated CoverageBuy$32.00
8/20/2026HC WainwrightReiterated RatingBuy ➝ Buy$50.00
8/11/2026Weiss RatingsInitiated CoverageSell (D+)
8/4/2026HC WainwrightReiterated RatingBuy ➝ Buy$50.00
7/15/2026HC WainwrightInitiated CoverageBuy$50.00
7/15/2026HC WainwrightInitiated CoverageBuy$50.00
7/7/2026Wolfe ResearchInitiated CoverageHold
6/9/2026UBS GroupDowngradeSell
5/27/2026Zacks ResearchUpgradeHold
5/26/2026CitigroupInitiated CoverageBuy$35.00
5/26/2026BNP Paribas ExaneDowngradeMarket Perform
5/26/2026Stifel NicolausInitiated CoverageBuy$30.00
5/26/2026JPMorgan Chase & Co.Initiated CoverageOverweight$42.00
5/26/2026Leerink PartnersInitiated CoverageOutperform$35.00
(Data available from 10/8/2021 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/12/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/11/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/10/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/8/2026
  • 15 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/8/2026

Current Sentiment

  • 15 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Seaport Therapeutics logo
Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.
Read More

Today's Range

Now: $17.97
Low: $17.67
High: $18.46

50 Day Range

MA: $22.54
Low: $17.37
High: $27.84

52 Week Range

Now: $17.97
Low: $14.85
High: $28.38

Volume

112,336 shs

Average Volume

225,096 shs

Market Capitalization

$961.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Seaport Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Seaport Therapeutics in the last year: BNP Paribas Exane, Citigroup Inc., HC Wainwright, JonesTrading, JPMorgan Chase & Co., Leerink Partners, Raymond James Financial, Inc., Seaport Research Partners, Stifel Nicolaus, UBS Group AG, Wall Street Zen, Weiss Ratings, Wolfe Research, and Zacks Research.
View the latest analyst ratings for SPTX.

What is the current price target for Seaport Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Seaport Therapeutics in the last year. Their average twelve-month price target is $38.57, suggesting a possible upside of 115.4%. HC Wainwright has the highest price target set, predicting SPTX will reach $50.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $30.00 for Seaport Therapeutics in the next year.
View the latest price targets for SPTX.

What is the current consensus analyst rating for Seaport Therapeutics?

Seaport Therapeutics currently has 1 sell rating, 3 hold ratings, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SPTX.

What other companies compete with Seaport Therapeutics?

Other companies that are similar to Seaport Therapeutics include Organon & Co., Regencell Bioscience, Tarsus Pharmaceuticals, Arcutis Biotherapeutics and MorphoSys. Learn More about companies similar to Seaport Therapeutics.

How do I contact Seaport Therapeutics' investor relations team?

Seaport Therapeutics' physical mailing address is 6 Tide Street, Suite 400, Boston, MA, 02110. The company's listed phone number is 617-807-4062 and its investor relations email address is [email protected]. The official website for Seaport Therapeutics is www.seaporttx.com. Learn More about contacing Seaport Therapeutics investor relations.